Peer-reviewed veterinary case report
Dog with MDR1 mutation had too much immune suppression
By Mackin, Andrew J et al.·Published in Journal of the American Animal Hospital Association·2020·From Mississippi State University College of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Excessive Cyclosporine-Associated Immunosuppression in a Dog Heterozygous for the MDR1 (ABCB1-1Δ) Mutation.
- Species:
- dog
Plain-English summary
A dog with immune-mediated hemolytic anemia was being treated with cyclosporine, a medication that suppresses the immune system. Despite receiving a low dose, the dog developed a secondary infection and showed signs of excessive immunosuppression. Tests revealed that the dog carried a genetic mutation (MDR1) that made it more sensitive to the effects of cyclosporine. This case emphasizes the importance of closely monitoring dogs on immunosuppressive therapy, especially if they are not responding as expected or develop infections. Adjusting the treatment based on individual responses can help ensure better outcomes.
People also search for: dog immune-mediated hemolytic anemia treatment · cyclosporine side effects in dogs · MDR1 mutation in dogs
Abstract
Pharmacodynamic monitoring was used to titrate cyclosporine dosing in a dog with immune-mediated hemolytic anemia. Development of a suspected secondary infection, with subsequent discovery of an unexpectedly high level of T-cell suppression despite a relatively low cyclosporine dose, prompted an investigation into the cause of possible excessive immunosuppression. Blood cyclosporine concentrations were within expected target ranges, and the dog was determined to be heterozygous for the multidrug resistance protein 1 (MDR1; ATP-binding cassette sub family B member 1-1Δ) gene mutation. The MDR1 mutation was suspected to have contributed to the excessive immunosuppression experienced by this patient. This case highlights the need to monitor immunosuppressive therapy in the individual patient, especially when the patient is not responding to therapy at typical dosages or when secondary infections develop at dosages lower than expected to cause significant immunosuppression. Pharmacodynamic monitoring can be used to help identify unexpected excessive immunosuppression in dogs receiving cyclosporine, and MDR1 genotyping should be further explored as a potential method of predicting and preventing its occurrence.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32182109/